Post-essential Thrombocythemia Myelofibrosis clinical trials at UCSD

• Study of CPI-0610 in Myelofibrosis (MF)

  open to eligible people ages 18 years and up

  A Phase 3, randomized, blinded study comparing CPI-0610 and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been exposed previously to Janus kinase inhibitors (JAKi). CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins. Evidence suggests that inhibition of both BET and JAK pathways can result in synergistic reduction of disease and overall improvement in the prognosis of MF.

  La Jolla, California and other locations

Last updated: November 19, 2021